Anemia in Chronic Kidney Disease (CKD)
Anemia in chronic kidney disease may cause fatigue, dizziness and shortness of breath. Learn how hemoglobin, iron tests and kidney care guide treatment.
Anemia related to chronic kidney disease involves a reduced number of red blood cells or low hemoglobin. Reduced erythropoietin production can contribute, but iron deficiency, inflammation, blood loss and other causes must also be assessed.
How kidney-related anemia may feel
Anemia means that the blood has too little hemoglobin to carry oxygen normally, although patients do not always notice symptoms immediately. A person with chronic kidney disease may gradually become unusually tired after walking, need longer recovery after ordinary activities or feel lightheaded when standing. Climbing stairs can become more difficult, and some notice palpitations or shortness of breath on exertion. These complaints are not specific to anemia and may also arise from heart disease, fluid overload, poor sleep or medications. A pale appearance is not a reliable way to estimate hemoglobin. Some people with a slow decline adapt and report little change despite an abnormal blood count. Others are affected significantly at similar levels. The clinician therefore considers both the actual laboratory results and the person's usual functioning, symptoms and other conditions.
Why anemia develops in kidney disease
Healthy kidneys help produce erythropoietin, a hormone that signals the bone marrow to make red blood cells. As kidney function declines, reduced erythropoietin activity can contribute to anemia, but this is rarely the only issue. Iron deficiency, inflammation, blood loss, nutritional deficiencies and shortened red cell survival may also play roles. For patients on dialysis, repeated blood sampling, access-related loss and ongoing inflammation can be relevant. Hemoglobin can decline because of gastrointestinal bleeding or another illness even when kidney disease is present. The cause matters because iron replacement, erythropoiesis-stimulating treatment and investigation of bleeding are not interchangeable. Patients should not assume that a low hemoglobin is automatically caused by the kidneys or that beginning dialysis will correct it. A thorough history and appropriate tests help identify treatable contributors.
When symptoms need urgent assessment
New severe breathlessness, chest pain, fainting, major dizziness with instability or rapidly worsening weakness requires prompt medical assessment. A significant sudden drop in hemoglobin, especially with suspected bleeding, is different from stable mild anemia identified during chronic disease monitoring. Black stools, vomiting blood or other concerning bleeding symptoms should be communicated urgently to medical professionals. Patients on dialysis should report major blood loss, unusual access bleeding and changes in exercise tolerance. Anemia can worsen an existing heart condition, but breathlessness may also reflect fluid overload or another emergency. The urgency is determined by symptoms, hemoglobin trend, circulation and suspected cause. A routine ZagrebMed inquiry is not appropriate for severe acute symptoms or uncontrolled bleeding.
How doctors investigate anemia
Evaluation starts with a complete blood count and hemoglobin, often including red cell indices that help characterize the anemia. Kidney function and a history of inflammation, bleeding, diet and medications provide context. Iron assessment commonly includes ferritin and transferrin saturation, which must be interpreted carefully because inflammation can alter ferritin. Depending on the patient, clinicians may check vitamin B12, folate, blood loss or other causes. Earlier hemoglobin results show whether the decline was slow or sudden. The KDIGO 2026 guideline provides updated recommendations for assessing anemia in people with CKD, including those on dialysis or after transplantation. A single hemoglobin reading rarely identifies the whole cause or the right therapy. Tests and repeat intervals are individualized rather than automatically identical for everyone.
What the next step may involve
A nephrology consultation can consider how impaired kidney function contributes to anemia while checking other common causes such as iron deficiency or blood loss. A creatinine and eGFR blood test provides kidney filtration context, but diagnosis of anemia requires a blood count and may call for iron and other tests.
Management is based on the cause, severity, symptoms and patient preferences. Some people benefit from treatment of iron deficiency, while selected patients may receive an erythropoiesis-stimulating agent under specialist supervision. The decision depends on hemoglobin, iron status, dialysis status and the potential benefits and risks. ESA treatment requires monitoring and is not intended to normalize hemoglobin at any cost; excessive correction may increase cardiovascular or thrombotic risk. Blood transfusion may be considered in selected circumstances but has its own risks and implications. Starting dialysis is not the standard treatment for anemia alone. The kidney team also addresses inflammation, blood loss and nutritional factors as appropriate. Follow-up includes blood count, iron indices, treatment tolerance and whether daily functioning has improved without undue adverse effects.
How the next step is chosen
A gradual fall in hemoglobin during stable chronic kidney disease is assessed differently from sudden anemia with suspected bleeding, chest pain or fainting. Clinicians review hemoglobin trends, ferritin and transferrin saturation, inflammation, nutrition and other possible causes before choosing treatment. Dialysis status matters: the 2026 KDIGO anemia guideline generally favors intravenous rather than oral iron when initiating iron treatment in people receiving hemodialysis, while choices for those not receiving hemodialysis depend on the individual circumstances. Erythropoiesis-stimulating medicines are considered after correctable causes have been addressed and require monitoring for benefits and potential harms. The aim is safe symptom management, not restoring hemoglobin to a universally normal value. Anemia alone is not an indication to start dialysis.
What to prepare before a medical appointment
For a planned appointment, bring several recent complete blood counts with dates, iron studies if available, creatinine and eGFR results, medication details and previous treatments for anemia. Describe tiredness, dizziness, exercise tolerance, breathlessness, palpitations and any signs of bleeding. Mention whether you already receive dialysis or have a kidney transplant because that changes treatment choices and monitoring. Patients from abroad may send reports to ZagrebMed before a nonurgent consultation in Zagreb, but provider availability and clinical suitability must be confirmed. Do not begin iron supplements, erythropoiesis-stimulating medicines or stop existing prescriptions without medical advice. Serious breathing difficulty, chest pain or acute bleeding requires direct urgent care.
A planned assessment in nephrology can connect the anemia findings with the patient's kidney disease, while the treating clinician decides whether further tests or treatment are appropriate.
For confirmed CKD, ongoing kidney disease monitoring can include hemoglobin trends and relevant iron studies when indicated. Anemia treatments are selected after identifying contributing causes; hemodialysis is not prescribed simply to correct anemia in a patient who otherwise does not require kidney replacement therapy.
What the KDIGO 2026 anemia guideline changes
The 2026 KDIGO guideline emphasizes that anemia in chronic kidney disease should not automatically be attributed to reduced erythropoietin. Its initial evaluation includes a complete blood count, reticulocyte count, ferritin and transferrin saturation (TSAT). When results suggest a different cause, a clinician may investigate bleeding, inflammation, vitamin B12 or folate deficiency and other diseases. Hemoglobin describes the severity of anemia, while ferritin and TSAT help assess whether iron treatment may be useful; no single test establishes every cause.
Management is individualized. Oral or intravenous iron may be considered according to dialysis status, iron findings, tolerance and clinical context. If correctable causes have been addressed, an erythropoiesis-stimulating agent may be discussed; KDIGO generally prefers these agents over HIF-prolyl hydroxylase inhibitors as first-line treatment when appropriate. Hemoglobin is not simply pushed into the normal range: treatment goals balance symptom relief against cardiovascular and other harms. Blood transfusion is reserved for selected clinical situations rather than routine management of stable chronic anemia.
For nonurgent evaluation in Zagreb, a nephrology consultation may review the combined kidney and hematology findings. Dr. Igor Žabić, a nephrology subspecialist practicing at Sinteza Polyclinic, is one confirmed ZagrebMed network physician. Patients should share previous hemoglobin values, ferritin and TSAT results, kidney tests, medication history and any dialysis records. These links do not mean that iron infusions or anemia-specific medications are automatically offered at Sinteza.
Clinical sources
- KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease
- NIDDK: Anemia in Chronic Kidney Disease
- KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease